Nebraska is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Omaha, Lincoln, Kearney and Grand Island. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: Skyline Medical Center, PC/CCT Research, Elkhorn, Nebraska
Conditions: Lower Respiratory Tract Illness
Register for Updates
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
Conditions: Mucopolysaccharidosis I (MPS I)
Register for Updates
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Register for Updates
Combining a Smartphone App With Medications to Manage Heavy Drinking
NCT06303778
Recruiting
One in 10 Veterans have an alcohol use disorder. However, few Veterans receive evidenced-based psychosocial interventions or medications to treat alcohol use disorder. Barriers to receiving these treatments include long wait times, stigma, and long distances from treatment facilities. Even fewer Veterans receive psychosocial and medication interventions together, despite clinical practice guidelines recommending both and evidence of better outcomes. Expanding access to these treatments in primar... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/15/2024
Locations: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
NCT05860296
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Register for Updates
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
NCT06690801
Recruiting
The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk s... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
11/13/2024
Locations: University of Nebraska Medical Center / Children's Hospital and Medical Center, Omaha, Nebraska
Conditions: Acute Respiratory Distress Syndrome
Register for Updates
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
NCT06058455
Recruiting
The goal of this randomized trial is to test whether the Internet-Delivered Enhanced Assess, Acknowledge, Act (IDEA3) sexual assault resistance education intervention reduces sexual violence victimization in undergraduate women. Participants in the intervention group will be asked to attend four three-hour group sessions of a sexual assault resistance program called IDEA3 with a partner, as well as fill out a number of surveys. Participants in the control group will be asked to attend a one-hou... Read More
Gender:
ALL
Ages:
Between 17 years and 24 years
Trial Updated:
11/13/2024
Locations: University of Nebraska - Lincoln, Lincoln, Nebraska
Conditions: Sexual Assault
Register for Updates
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT06026332
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Ferring Investigational Site, Omaha, Nebraska
Conditions: Bladder Cancer
Register for Updates
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2024
Locations: MBX Biosciences Investigational Site, Omaha, Nebraska
Conditions: Hypoparathyroidism
Register for Updates
Smart Checklist Implementation for Pediatric Tracheal Intubations in the ICU- Multicenter Study
NCT06085326
Recruiting
The purpose of the study is to implement a patient-provider dyad tailored, Electronic Health Record (EHR)-informed, digitized Smart Checklist as a Quality Improvement (QI) intervention to support bedside clinician teams to reduce Adverse Airway Outcomes (AAO) across 6 diverse pediatric intensive care units (ICUs).
Gender:
ALL
Ages:
19 years and below
Trial Updated:
11/08/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Intubation Complication
Register for Updates
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
NCT06190886
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Nebraska Cancer Specialists (NCS), Omaha, Nebraska
Conditions: Advanced Cancer, Solid Tumor, Metastatic Cancer
Register for Updates
A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection
NCT06168669
Recruiting
Purpose: To validate the safety and effectiveness of xBar monitoring tool for detection of post-operative anastomotic leaks in subjects undergoing rectal/sigmoid resections with anastomosis. The clinical team is blinded to the leak detection of the xBar system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
11/03/2024
Locations: Bryan Medical Center, Lincoln, Nebraska
Conditions: Colorectal Surgery, Anastomotic Leak
Register for Updates